BS_A14Z8BBK
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- os_event
- false
- age_years
- 10.17
- sex
- F
- race
- White
- umap1_2d
- 6.425118485
- umap2_2d
- 5.678353386
- umap1_3d
- 3.037164714
- umap2_3d
- -0.414093878
- umap3_3d
- -2.019482785
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.430
- HEDGEHOG_SIGNALING+0.240
- KRAS_SIGNALING_DN+0.240
- ESTROGEN_RESPONSE_EARLY+0.150
- UV_RESPONSE_DN+0.110
- NOTCH_SIGNALING+0.070
- SPERMATOGENESIS+0.060
- PROTEIN_SECRETION+0.050
- ANDROGEN_RESPONSE+0.040
- ESTROGEN_RESPONSE_LATE-0.010
Top 10 suppressed
- E2F_TARGETS-0.600
- MYC_TARGETS_V2-0.600
- MYC_TARGETS_V1-0.540
- DNA_REPAIR-0.520
- G2M_CHECKPOINT-0.510
- OXIDATIVE_PHOSPHORYLATION-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.420
- INTERFERON_ALPHA_RESPONSE-0.340
- APOPTOSIS-0.320
- MITOTIC_SPINDLE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG355 | — | — | 0.896 |
| 2 | BS_TE0GVDNG | Med | Medulloblastoma | 0.892 |
| 3 | C3N-03921 | — | cohortA1 | 0.892 |
| 4 | BS_063ERW0R | pilocytic astrocytoma | — | 0.891 |
| 5 | BS_CQSAJ7BF | DNET | — | 0.891 |
| 6 | BS_W9AT0MR7 | Med | Medulloblastoma | 0.890 |
| 7 | C3N-02950 | — | cohortA1 | 0.889 |
| 8 | MNG786 | — | — | 0.884 |
| 9 | TCGA-44-6148-01A-11R-1755-07 | — | cohortA1 | 0.881 |
| 10 | BS_G9XE3N9T | pilocytic astrocytoma | — | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.430 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |